Authors

Latest:

Rugo Covers Scope of Recent Breast Cancer Advances

Hope S. Rugo, MD, discusses a variety of agents for the treatment of patients with ER-positive breast cancer, such as mTOR inhibitors, PI3K inhibitors, and CDK4/6 inhibitors, in addition to novel targeted therapies being investigated in TNBC.

Cheryl Alkon

Latest:

Building Foundations for Understanding Drug Mechanisms in Oncology

A 2018 Giants of Cancer Care award winner for Drug Development, Joseph R. Bertino, MD, was an early pioneer in developing the understanding of methotrexate and its administration in cancer. His work has served as a platform for much broader investigation into the optimal use of other cancer agents. Along the way, Bertino has mentored many leaders in oncology and hematology and earned international recognition.

Cheryl Zigrand

Latest:

Experts Share Hopes for the Future of Myeloma Treatment

The data being amassed about novel multiple myeloma therapies have the potential to change the way patients with relapsed or refractory disease are currently being treated.

Chiara Cremolini, MD

Latest:

Dr Cremolini on the Implications of the TRANSMET Trial in Colorectal Liver Metastases

Chiara Cremolini, MD, PhD, discusses the implications of the TRANSMET trial in patients with unresectable colorectal liver metastases.

Ching-Hon Pui, MD

Latest:

Dr. Pui on Utilizing CAR T-Cell Therapy in Pediatric ALL

Ching-Hon Pui, MD, discusses the use of CAR T-cell therapy in patients with relapsed/refractory acute lymphocytic leukemia.

Chip Landen, MD

Latest:

Dr. Landen Discusses p53 Mutations in Ovarian Cancer

Chip Landen, MD, associate professor, Division of Gynecologic Oncology, University of Virginia Health System, discusses the role of p53 mutations in patients with ovarian cancer.

Chirag Shah, MD

Latest:

Dr Shah on Research to Minimize Surgical Intervention in Locoregional Breast Cancer

Chirag Shah, MD, discusses ongoing clinical trials aiming to minimize surgical intervention in locoregional breast cancer.

Chloe E. Atreya, MD, PhD

Latest:

Dr. Atreya Discusses Maintenance Therapy for CRC

Chloe E. Atreya, MD, PhD, assistant clinical professor, Department of Medicine, University of California, San Francisco Helen Diller Family Comprehensive Cancer Center, discusses maintenance therapy for patients with colorectal cancer.

Chong-Xian Pan, MD, PhD

Latest:

Patient-Derived Xenografts Could Improve Precision Medicine Outcomes

Researchers at the UC Davis Comprehensive Cancer Center are personalizing treatment using tumor xenografts in mice to test and identify more precise treatments for bladder cancer patients.

Chris Parker, MD

Latest:

Dr. Parker on the Optimal Timing of Salvage Therapy in Prostate Cancer

Chris Parker, MD, discusses the optimal timing of salvage radiotherapy for men with prostate cancer.

Chris Parker, MD, FRCR, MRCP, Institute of Cancer Research, Royal Marsden Hospital

Chris Paton, BMBS, BMedSci

Latest:

Useless Medical Devices

Throughout history, the public's pursuit of good health has, in the absence of scientific method or even common sense, motivated the creation of some downright ridiculous medical devices.

Christen Brown, MS

Latest:

Oncology Fellows: Reminding Ourselves of How Far We've Come

For us, a group of 15 black students at Tulane University School of Medicine (TUSCOM), a visit to the Whitney Plantation in Edgard, Louisiana, was a no-brainer. The process of navigating medical school is pure hell at times, and you need inspiration wherever and whenever you can get it.

Christian Blank, MD, PhD

Latest:

Dr. Blank on the OpACIN, OpACIN-neo Trials in Stage III Macroscopic Melanoma

Christian U. Blank, MD, PhD, discusses the OpACIN and OPACIN-neo trials examining ipilimumab plus nivolumab in stage III macroscopic melanoma.

Christian G. Downs, JD, MHA

Latest:

Christian Downs on the 34th National Oncology Conference

Christian G. Downs, JD, MHA, executive director of the Association of Community Cancer Centers (ACCC), discusses the upcoming 34th National Oncology Conference, taking place October 18 to 20 in Nashville, Tennessee.

Christian Gisselbrecht, MD

Latest:

Dr. Christian Gisselbrecht on Outcomes of Relapsed DLBCL

Christian Gisselbrecht, MD, a Professor of Haematology in the Haemato-Oncology Department of Hôpital Saint-Louis, at Diderot University, Paris, discusses refractory disease in aggressive diffuse large b-cell lymphoma (DLBCL).

Christian Rolfo, MD, PhD

Latest:

Dr. Rolfo on Precision Medicine in Lung Cancer

Christian Diego Rolfo, MD, PhD, professor and unit coordinator at Antwerp University discusses the European perspective on precision medicine in lung cancer and the importance of clinical trials across different markets.

Christian Rolfo, MD, PhD, MHBA

Latest:

Dr. Rolfo Discusses the Potential Utility of Ceritinib

Christian Rolfo, MD, PhD, MHBA, head, phase I clinical trials unit, Antwerp University Hospital, Belgium, discusses the potential utility of ceritinib.

Christian Winther Eskelund, MD

Latest:

Dr. Eskelund on Outcomes of TP53-Mutated MCL

Christian Winther Eskelund, MD, Copenhagen University Hospital, Rigshospitalet, discusses outcomes for patients with TP53-mutated mantle cell lymphoma (MCL).

Christie J. Hilton, DO

Latest:

Dr Hilton on Trastuzumab Deruxtecan in HER2+ Metastatic Breast Cancer

Christie J. Hilton, DO, discusses the first-line standard of care and changes in the second-line SOC, including key findings from the phase 3 DESTINY-Breast03 trial, in patients with HER2-positive metastatic breast cancer.